ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) Short-Term Debt: €22.85 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:R9Z ImmuneOnco Biopharmaceuticals (Shanghai) Inc FRA:R9Z
6 GF Score
Price €0.37
! 5 Warning Signs
View Full Analysis

What is ImmuneOnco Biopharmaceuticals (Shanghai) Short-Term Debt?

ImmuneOnco Biopharmaceuticals (Shanghai) FRA:R9Z +11.52% 6 Short-Term Debt is €22.85 Mil as of Dec. 2025. GuruFocus rates FRA:R9Z with a GF Score™ of 6/100. The stock has 5 warning signs investors should review.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Short-Term Debt for the quarter that ended in Dec. 2025 was €22.85 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai)'s quarterly Short-Term Debt increased from Dec. 2024 (€13.23 Mil) to Jun. 2025 (€15.45 Mil) and increased from Jun. 2025 (€15.45 Mil) to Dec. 2025 (€22.85 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai)'s annual Short-Term Debt increased from Dec. 2023 (€7.70 Mil) to Dec. 2024 (€13.23 Mil) and increased from Dec. 2024 (€13.23 Mil) to Dec. 2025 (€22.85 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai) Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

ImmuneOnco Biopharmaceuticals (Shanghai) Short-Term Debt Related Terms

ImmuneOnco Biopharmaceuticals (Shanghai) Short-Term Debt Historical Data

* Premium members only.

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai) Short-Term Debt Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
0.00 0.00 7.70 13.23 22.85

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only 7.70 9.09 13.23 15.45 22.85
FRA:R9Z
6GF Score
ImmuneOnco Biopharmaceuticals (Shanghai) Inc FRA:R9Z
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €22.85 Mil mean?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a Short-Term Debt of €22.85 Mil as of Dec. 2025.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s Short-Term Debt too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Short-Term Debt is €22.85 Mil. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s Short-Term Debt compare to VRTX and REGN?
ImmuneOnco Biopharmaceuticals (Shanghai)'s Short-Term Debt of €22.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. ImmuneOnco Biopharmaceuticals (Shanghai)'s current Short-Term Debt is €22.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a current Short-Term Debt of €22.85 Mil. The current Short-Term Debt is €22.85 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z), the current Short-Term Debt is €22.85 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Other Exchanges 01541:Hong Kong
Address 1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score

Get the complete analysis for FRA:R9Z

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price